Novartis AG (NYSE:NVS) Shares Sold by CX Institutional

CX Institutional lessened its holdings in shares of Novartis AG (NYSE:NVS) by 1.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,539 shares of the company’s stock after selling 140 shares during the period. CX Institutional’s holdings in Novartis were worth $1,026,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Novartis by 115.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 231,792 shares of the company’s stock valued at $26,797,000 after buying an additional 124,111 shares during the period. CWA Asset Management Group LLC lifted its holdings in Novartis by 20.1% in the fourth quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company’s stock valued at $3,001,000 after acquiring an additional 5,164 shares during the period. Quantbot Technologies LP boosted its position in Novartis by 135.5% in the 3rd quarter. Quantbot Technologies LP now owns 39,976 shares of the company’s stock worth $4,598,000 after purchasing an additional 22,998 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Novartis by 13.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 157,256 shares of the company’s stock worth $18,088,000 after purchasing an additional 18,990 shares during the period. Finally, Natixis Advisors LLC increased its holdings in shares of Novartis by 2.9% during the 3rd quarter. Natixis Advisors LLC now owns 938,844 shares of the company’s stock valued at $107,986,000 after purchasing an additional 26,317 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on NVS shares. HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Erste Group Bank restated a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. Finally, BMO Capital Markets upped their price target on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a report on Wednesday, October 30th. Two analysts have rated the stock with a sell rating and six have issued a hold rating to the stock. According to data from MarketBeat, Novartis has an average rating of “Hold” and an average target price of $123.38.

Novartis Stock Down 0.1 %

NVS opened at $99.93 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. Novartis AG has a twelve month low of $92.35 and a twelve month high of $120.92. The company has a market cap of $204.25 billion, a PE ratio of 11.61, a price-to-earnings-growth ratio of 1.42 and a beta of 0.57. The company has a 50-day moving average price of $100.09 and a 200 day moving average price of $108.69.

Novartis (NYSE:NVS) last released its earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. Novartis had a return on equity of 34.80% and a net margin of 35.96%. The business had revenue of $12.82 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same quarter last year, the business posted $1.74 earnings per share. Sell-side analysts expect that Novartis AG will post 7.62 earnings per share for the current fiscal year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.